期刊
FUTURE ONCOLOGY
卷 18, 期 30S, 页码 23-32出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-0519
关键词
advanced leiomyosarcoma; growth modulation index; long responder; myxoid; round cell liposarcoma; soft tissue sarcoma; solitary fibrous tumor; trabectedin
类别
Trabectedin serves as a recommended second-line option for advanced soft tissue sarcoma, offering long-term tumor control and preserved quality of life. Three case studies demonstrate the lasting responses patients can achieve with second-line trabectedin.
As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can provide the necessary balance between long-term tumor control and preserved quality of life. Three case studies illustrate the long-lasting responses that patients can achieve with second-line trabectedin. A female patient with metastatic leiomyosarcoma maintained disease control for 2 years with trabectedin (x 41 cycles) with excellent tolerability and no relevant adverse events. At the time of writing, a male patient with a metastatic solitary fibrous tumor was asymptomatic after 30 cycles of trabectedin and treatment was ongoing. A young male patient with a recurrent, nonresectable, retroperitoneal myxoid/round cell liposarcoma was able to continue his sporting activities (triathlons) over 2 years with trabectedin (x 14 cycles) plus watchful waiting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据